Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04472663 · ClinicalTrials.gov registry record
Participant Reported Outcomes and Treatment Experiences in Kidney Cancer
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 5
- Enrollment target
NCT04472663: Completed study, sponsored by Bristol-Myers Squibb.
NCT04472663 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04472663 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
The purpose of this observational study is to collect contemporary real-world treatment patterns, clinical outcomes, humanistic burden (including patient-reported disease-specific Health-related Quality of Life (HRQoL), and treatment- related adverse events (AEs) or adverse reactions (ARs) among Advanced Renal Cell Carcinoma (aRCC) patients initiating first-line systemic therapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-07-06 |
| Est. Completion | 2020-12-09 |
What the finished NCT04472663 record still lists
NCT04472663 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04472663 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04472663 about?
NCT04472663 is a clinical study titled "Participant Reported Outcomes and Treatment Experiences in Kidney Cancer". The purpose of this observational study is to collect contemporary real-world treatment patterns, clinical outcomes, humanistic burden (including patient-reported disease-specific Health-related Quality of Life (HRQoL), and treatment- related adverse events (AEs) or adverse reactions (ARs) among Adv...
What is the current status of trial NCT04472663?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2020-07-06. Estimated completion is 2020-12-09.
Who is sponsoring clinical trial NCT04472663?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI